Lennox-Gastaut Syndrome Treatment Market by Type (Surgical Treatment, Non-Surgical Treatment), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2019 to 2026
Published On: May 2019
 
Report ID:386029
 
 
Pages: N/A




Global lennox-gastaut syndrome treatment market is expected to reach USD XX million by 2026, at a CAGR of XX% from 2019 to 2026. The key contributing factors for the market growth are the availability of limited number of treatments and rising funds by non-profit organization such as national organization for rare disorders.

Market Overview:

Lennox-gastaut syndrome (LGS) is a severe childhood-onset electroclinical syndrome, also known as pediatric epilepsy syndrome characterized by multiple tonic-clonic seizures, mental retardation, reduced intellectual powder, and abnormal findings on electroencephalograph.  LGS starts between 2 to 8 years kids and is more common in boys than in girls. The identification and treatment of lennox-gastaut syndrome (LGS) in the early stages are necessary as it may have life-threatening consequences in pediatric patients. In addition, the governments, as well as non-governmental organizations, are promoting the initiatives to provide education to the peoples as well as offering medical care and support for the lennox-gastaut syndrome (LGS) patients. This will further drive the market growth in the upcoming years.

Report Description:

  • The base year for the study has been considered 2018, historic year 2016 and 2017, the forecast period considered is from 2019 to 2026. The global lennox-gastaut syndrome treatment market is analysed on the basis of  Value (USD Million)
  • The study delivers a comprehensive analysis of global lennox-gastaut syndrome treatment market by type and regions.
  • The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
  • Porter’s Five Forces model is used in order to recognize the competitive scenario in the global lennox-gastaut syndrome treatment market. This report incorporates the industry analysis which is focused on providing an extensive view of the lennox-gastaut syndrome treatment market.
  • The study also includes attractiveness analysis of type and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
  • The report provides company profile of the key players operating in the lennox-gastaut syndrome treatment market and a comparative analysis based on their business overviews, product offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
  • The market estimates have been evaluated by considering the effect of different political, economic, social, technological and legal factors which are based on our extensive secondary research, primary research, and in-house databases.

Market Dynamics:

Drivers:

  • Availability of limited number of treatments
  • Rising funds by non-profit organization such as National Organization for rare disorders

Restraints:

  • High cost of treatment

Opportunities:

  • Growing awareness of lennox-gastaut syndrome (LGS)
  • Increasing investments in R&D

Challenges:

  • Controlling seizures in patients with lennox-gastaut syndrome (LGS)

Global Lennox-Gastaut Syndrome Treatment Market Key Findings:

All the segments have been analysed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment.

Segmentation Analysis:

The lennox-gastaut syndrome treatment market is segmented on the basis of type.

  • Type segment includes surgical treatment and non-surgical treatment. The non-surgical treatment segment is anticipated to grow with highest market share owing to the recent lennox-gastaut syndrome (LGS) drug approvals and adoption of ketogenic diet globally.  The approved medications such as lamotrigine, topiramate, rufinamide, felbamate and clobazam have reduced seizure burden of the surgical treatments.

Regional Segmentation Analysis:

The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and Middle East and Africa. North America region held the largest market share in 2018 where as the Asia Pacific region held the second dominant position in the global lennox-gastaut syndrome treatment market

  • Increasing awareness of lennox-gastaut syndrome, increasing investments in research on lennox-gastaut syndrome, and strategic agreements among companies, and rapid technological advancements are some of the factors that led to the growth of lennox-gastaut syndrome treatment market in North America region.
  • Asia Pacific is fastest growing region due to the increasing adoption of lennox-gastaut syndrome treatment and high prevalence rate of lennox-gastaut syndrome.

Global Lennox-Gastaut Syndrome Treatment Market Competitive Analysis:

Key players in the lennox-gastaut syndrome treatment market are INSYS Therapeutics Inc., Eisai Inc., GW Research Ltd., Zogenix, Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, H. Lundbeck A/S, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Ortho-McNeil Pharmaceutical Ltd., Supernus Pharmaceuticals, Inc., and others. The Eisai Co., Ltd., GlaxoSmithKline plc., H. Lundbeck A/S, Johnson & Johnson Services, Inc., and Supernus Pharmaceuticals, Inc. are the top leading players of the market.

*All our reports are customizable as per customer requirements

This study forecasts revenue and volume growth at global, regional, and country levels from 2016 to 2026. Fior Market Research has segmented the global lennox-gastaut syndrome treatment market on the basis of below mentioned segments:

Global Lennox-Gastaut Syndrome Treatment Market, By Type:

  • Surgical Treatment
  • Non-Surgical Treatment

Global Lennox-Gastaut Syndrome Treatment Market, By Regions:

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Sweden
  • Netherlands
  • U.K.
  • Italy
  • Spain
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of Asia-Pacific
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of  Middle East and Africa

1. Introduction
   1.1. Objectives of the Study
   1.2. Market Definition
   1.3. Research Scope
   1.4. Currency

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
   4.1. Porter’s Five Forces Analysis
   4.2. Value Chain Analysis
   4.3. Top Investment Pockets
        4.3.1. Market Attractiveness Analysis By Type
        4.3.2. Market Attractiveness Analysis By Region
   4.4. Industry Trends

5. Market Dynamics
   5.1. Market Evaluation
   5.2. Drivers
        5.2.1. Availability Of Limited Number Of Treatments
        5.2.2. Rising Funds By Non-Profit Organization Such As National Organization For Rare Disorders
   5.3. Restraints
        5.3.1. High Cost Of Treatment
   5.4. Opportunities
        5.4.1. Growing Awareness Of Lennox-Gastaut Syndrome (LGS)
        5.4.2. Increasing Investments In R&D
   5.5. Challenges
        5.5.1. Controlling Seizures In Patients With Lennox-Gastaut Syndrome (LGS)

6. Global Lennox-Gastaut Syndrome Treatment Market Analysis and Forecast, By Type
   6.1. Segment Overview
   6.2. Surgical Treatment
   6.3. Non-Surgical Treatment

7. Global Lennox-Gastaut Syndrome Treatment Market Analysis and Forecast, By Regional Analysis
   7.1. Segment Overview
   7.2. North America
        7.2.1. U.S.
        7.2.2. Canada
        7.2.3. Mexico
   7.3. Europe
        7.3.1. Germany
        7.3.2. France
        7.3.3. Sweden
        7.3.4. Netherlands
        7.3.5. U.K.
        7.3.6. Italy
        7.3.7. Spain
        7.3.8. Turkey
        7.3.9. Switzerland
        7.3.10. Belgium
        7.3.11. Rest of Europe
   7.4. Asia-Pacific
        7.4.1. Japan
        7.4.2. China
        7.4.3. India
        7.4.4. South Korea
        7.4.5. Australia
        7.4.6. Singapore
        7.4.7. Malaysia
        7.4.8. Thailand
        7.4.9. Indonesia
        7.4.10. Philippines
        7.4.11. Rest of Asia-Pacific
   7.5. South America
        7.5.1. Brazil
        7.5.2. Argentina
        7.5.3. Colombia
        7.5.4. Rest of South America
   7.6. Middle East and Africa
        7.6.1. Saudi Arabia
        7.6.2. UAE
        7.6.3. Egypt
        7.6.4. Nigeria
        7.6.5. South Africa
        7.6.6. Rest of  Middle East and Africa

8. Global Lennox-Gastaut Syndrome Treatment Market-Competitive Landscape
   8.1. Overview
   8.2. Market Share of Key Players in the Lennox-Gastaut Syndrome Treatment Market
        8.2.1. Global Company Market Share
        8.2.2. North America Company Market Share
        8.2.3. Europe Company Market Share
        8.2.4. APAC Company Market Share
   8.3. Competitive Situations and Trends
        8.3.1. Product Launches and Developments
        8.3.2. Partnerships, Collaborations, and Agreements
        8.3.3. Mergers & Acquisitions
        8.3.4. Expansions

9. Company Profiles
   9.1. INSYS Therapeutics Inc.
        9.1.1. Business Overview
        9.1.2. Company Snapshot
        9.1.3. Company Market Share Analysis
        9.1.4. Company Product Portfolio
        9.1.5. Recent Developments
        9.1.6. SWOT Analysis
   9.2. Eisai Inc.
        9.2.1. Business Overview
        9.2.2. Company Snapshot
        9.2.3. Company Market Share Analysis
        9.2.4. Company Product Portfolio
        9.2.5. Recent Developments
        9.2.6. SWOT Analysis
   9.3. GW Research Ltd.
        9.3.1. Business Overview
        9.3.2. Company Snapshot
        9.3.3. Company Market Share Analysis
        9.3.4. Company Product Portfolio
        9.3.5. Recent Developments
        9.3.6. SWOT Analysis
   9.4. Zogenix, Inc.
        9.4.1. Business Overview
        9.4.2. Company Snapshot
        9.4.3. Company Market Share Analysis
        9.4.4. Company Product Portfolio
        9.4.5. Recent Developments
        9.4.6. SWOT Analysis
   9.5. Johnson & Johnson Pharmaceutical Research & Development, LLC
        9.5.1. Business Overview
        9.5.2. Company Snapshot
        9.5.3. Company Market Share Analysis
        9.5.4. Company Product Portfolio
        9.5.5. Recent Developments
        9.5.6. SWOT Analysis
   9.6. H. Lundbeck A/S
        9.6.1. Business Overview
        9.6.2. Company Snapshot
        9.6.3. Company Market Share Analysis
        9.6.4. Company Product Portfolio
        9.6.5. Recent Developments
        9.6.6. SWOT Analysis
   9.7. GlaxoSmithKline plc
        9.7.1. Business Overview
        9.7.2. Company Snapshot
        9.7.3. Company Market Share Analysis
        9.7.4. Company Product Portfolio
        9.7.5. Recent Developments
        9.7.6. SWOT Analysis
   9.8. Valeant Pharmaceuticals International, Inc.
        9.8.1. Business Overview
        9.8.2. Company Snapshot
        9.8.3. Company Market Share Analysis
        9.8.4. Company Product Portfolio
        9.8.5. Recent Developments
        9.8.6. SWOT Analysis
   9.9. Ortho-McNeil Pharmaceutical Ltd.
        9.9.1. Business Overview
        9.9.2. Company Snapshot
        9.9.3. Company Market Share Analysis
        9.9.4. Company Product Portfolio
        9.9.5. Recent Developments
        9.9.6. SWOT Analysis
   9.10. Supernus Pharmaceuticals, Inc.
        9.10.1. Business Overview
        9.10.2. Company Snapshot
        9.10.3. Company Market Share Analysis
        9.10.4. Company Product Portfolio
        9.10.5. Recent Developments
        9.10.6. SWOT Analysis

 


List of Figures 

1. Global Lennox-Gastaut Syndrome Treatment Market Segmentation

2. Lennox-Gastaut Syndrome Treatment Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Lennox-Gastaut Syndrome Treatment Market Attractiveness Analysis By Type

9. Global Lennox-Gastaut Syndrome Treatment Market Attractiveness Analysis By Region

10. Global Lennox-Gastaut Syndrome Treatment Market: Dynamics

11. Global Lennox-Gastaut Syndrome Treatment Market Share By Type (2018 & 2026)

12. Global Lennox-Gastaut Syndrome Treatment Market Share By Region (2018 & 2026)

13. Global Lennox-Gastaut Syndrome Treatment Market Share By Company (2018)

 

List of Table

1. Global Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

2. Global Surgical Treatment Lennox-Gastaut Syndrome Treatment Market, By Region, 2016–2026 (USD Million) 

3. Global Non-Surgical Treatment Lennox-Gastaut Syndrome Treatment Market, By Region, 2016–2026 (USD Million) 

4. Global Lennox-Gastaut Syndrome Treatment Market, By Region, 2016–2026 (USD Million) 

5. North America Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

6. U.S. Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

7. Canada Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

8. Mexico Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

9. Europe Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

10. Germany Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

11. France Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

12. Sweden Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

13. Netherlands Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

14. U.K. Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

15. Italy Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

16. Spain Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

17. Turkey Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

18. Switzerland Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

19. Belgium Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

20. Asia Pacific Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

21. Japan Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

22. China Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

23. India Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

24. South Korea Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

25. Australia Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

26. Singapore Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

27. Malaysia Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

28. Thailand Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

29. Indonesia Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

30. Philippines Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

31. South America Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

32. Brazil Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

33. Argentina Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

34. Colombia Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

35. Middle East and Africa Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

36. Saudi Arabia Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

37. UAE Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

38. Egypt Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

39. Nigeria Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 

40. South Africa Lennox-Gastaut Syndrome Treatment Market, By Type, 2016–2026 (USD Million) 



Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \
   Payment Mode



For More Information

   For More Information

If you have any query? Please contact us

sales@fiormarkets.com
+1-201-465-4211


Copyright © 2020 Fior Market Research LLP, All Rights Reserved.